export const introductionContentSection = `
        <div class="font-serif text-md font-bold">
        What is the purpose of this consent?        
        </div>

        <p class="text-sm font-san">
        You are invited to take part in this study because you have <span style="color: #008764"> human epidermal growth factor
        receptor 2 positive (HER2-positive) metastatic breast cancer (MBC).</span> HER2-positive MBC
        means that your tumour has tested positive for a protein called HER2 that promotes the
        growth of cancer cells and has caused the cancer to spread from your breast to the other
        parts of your body. <br/><br/>
        Participation requires your written consent. This Informed Consent Form gives an explanation about what the study
        involves, including:<br/><br/>
        1) The purpose of this study and what you will be asked to do as part of this study;<br/><br/>
        2) The information that may be collected from you as part of this study and how your information will be used or disclosed in the study;<br/><br/>
        3) The potential risks and discomforts associated with this study; and<br/><br/>
        4) How you may withdraw from the study and what happens to your information after you withdraw.<br/><br/>
        </p>

        <div class="font-serif text-md font-bold"  id="Voluntary Decision">
            Your decision to participate is voluntary    
        </div>

        <p class="text-sm font-san">
        You have a choice whether or not you would like to participate.
        Your cancer may or may not improve if you join
        the study, however the information we get from this study might help other patients with
        the same kind of cancer in the future.<br/><br/>
        Please take as much time as you need to make a decision about whether or not you would
        like to participate in this study. It may be helpful to talk with your friends and family as you
        make this decision.<br/><br/>
        If you join the study, you can leave at any time (see “Section 14” for more details). Leaving
        will not affect your care. If you choose to leave the study, please let your study doctor know
        as soon as possible. Please consider the study time commitments and responsibilities as a
        research patient when you are deciding to take part.
        If you do not join the study, you will continue to receive care for your HER2-positive MBC.
        Your study doctor or treating physician will talk to you about other possible treatments and
        their risks and benefits.        
        </p>
`

export const introductionAudioSection = 
`
        What is the purpose of this consent?       

        You are invited to take part in this study because you have human epidermal growth factor
        receptor 2 positive (HER2-positive) metastatic breast cancer (MBC).</span> HER2-positive MBC
        means that your tumour has tested positive for a protein called HER2 that promotes the
        growth of cancer cells and has caused the cancer to spread from your breast to the other
        parts of your body. 

        Participation requires your written consent. This Informed Consent Form gives an explanation about what the study
        involves, including: 

        1) The purpose of this study and what you will be asked to do as part of this study;
        2) The information that may be collected from you as part of this study and how your information will be used or disclosed in the study;
        3) The potential risks and discomforts associated with this study; and
        4) How you may withdraw from the study and what happens to your information after you withdraw.

        Your decision to participate is voluntary  

        You have a choice whether or not you would like to participate.
        Your cancer may or may not improve if you join
        the study, however the information we get from this study might help other patients with
        the same kind of cancer in the future.<br/><br/>
        Please take as much time as you need to make a decision about whether or not you would
        like to participate in this study. It may be helpful to talk with your friends and family as you
        make this decision.<br/><br/>
        If you join the study, you can leave at any time (see “Section 14” for more details). Leaving
        will not affect your care. If you choose to leave the study, please let your study doctor know
        as soon as possible. Please consider the study time commitments and responsibilities as a
        research patient when you are deciding to take part.
        If you do not join the study, you will continue to receive care for your HER2-positive MBC.
        Your study doctor or treating physician will talk to you about other possible treatments and
        their risks and benefits.     
`